Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ravagalimab in moderately to severely active primary Sjogren's syndrome
NL-OMON48111Phase 2Withdrawn
- Sponsor
- AbbVie Inc.
- Start
- Dec 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Sjögren's syndrome (SS) comparing Ravagalimab with Placebo (2 arms). Primary endpoint: Change from baseline in EULAR Sjogren's Syndrome Disease Activity Index. Planned start Dec 2019; status: withdrawn.
02
Drugs
ravagalimab
03
Conditions
Sjögren's syndrome (SS)
Beyond the preview
Go deeper on NL-OMON48111.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON48111.